Limited Survival Benefit of Short-Course Neoadjuvant Gemcitabine Plus Nab-Paclitaxel for Resectable Pancreatic Cancer: A Prospective Phase II Study With a Propensity Score–Matched Analysis

This publication has 30 references indexed in Scilit:

• Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)—a randomized phase II trial of the AIO pancreatic cancer group
  Annals of Oncology, 2022
• Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma
  JAMA Oncology, 2021
• A systematic assessment of statistics, risk factors, and underlying features involved in pancreatic cancer
  Cancer Epidemiology, 2019
• International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017
  Pancreatology, 2018
• Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer
  Cancer Chemotherapy and Pharmacology, 2016
• Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer
  JAMA, 2013
• nab-Paclitaxel mechanisms of action and delivery
  Journal of Controlled Release, 2013
• Delayed gastric emptying (DGE) after pancreatic surgery: A suggested definition by the International Study Group of Pancreatic Surgery (ISGPS)
  Surgery, 2007
• Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
  JAMA, 2007
• Preoperative Chemoradiation and Pancreaticoduodenectomy for Adenocarcinoma of the Pancreas
  Archives of Surgery, 1992